Development of Melioidosis Diagnostic Assay System
- Conditions
- Health Condition 1: B998- Other infectious disease
- Registration Number
- CTRI/2020/06/025951
- Lead Sponsor
- InBios International Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
At least 5 years of age.
Subject able to give written informed consent/assent as appropriate. Present with at least one of the following symptoms of melioidosis:
Sepsis with unknown cause at the time of study enrollment, or Suspected cases of melioidosis by physician with a wide range of symptoms including: Type 2 diabetes with ulceration and abscesses and/or unhealed wounds; Swelling, open wounds/skin abrasions with pus; Multiple abscesses in kidneys, liver, spleen, prostate; Respiratory tract symptoms (sore throat, shortness of breath, pneumonia, cough); Fever with chills and other signs and symptoms consistent with melioidosis; Headache and other signs and symptoms consistent with melioidosis; Muscle soreness and other signs and symptoms consistent with melioidosis; Weight loss and other signs and symptoms consistent with melioidosis.
Currently taking or have taken ceftazidime or meropenem targeting B. pseudomallei in the last 48 hours.
Previous enrollment in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate and marketised a noble diagnostic tool for one of the infectious disease like MelioidosisTimepoint: One day for each subject for AMD testing, and up to 6 days longer for collection of additional specimens for a second reference test
- Secondary Outcome Measures
Name Time Method Active Melioidosis Detect Rapid test will help to diagnose patients with melioidosis within short period of timeTimepoint: One day for each subject for AMD testing, and up to 6 days longer for collection of additional specimens for a second reference test